

# Thierry Calandra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8641605/publications.pdf>

Version: 2024-02-01

201  
papers

47,714  
citations

5574

82  
h-index

2571

195  
g-index

211  
all docs

211  
docs citations

211  
times ranked

30193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. <i>Critical Care Medicine</i> , 2008, 36, 296-327.	0.9	7,331
2	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Critical Care Medicine</i> , 2004, 32, 858-873.	0.9	4,598
3	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	5.8	4,375
4	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Intensive Care Medicine</i> , 2004, 30, 536-555.	8.2	2,079
5	Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. <i>Intensive Care Medicine</i> , 2008, 34, 17-60.	8.2	2,078
6	Macrophage migration inhibitory factor: a regulator of innate immunity. <i>Nature Reviews Immunology</i> , 2003, 3, 791-800.	22.7	2,045
7	2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2002, 34, 730-751.	5.8	1,738
8	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
9	MIF as a glucocorticoid-induced modulator of cytokine production. <i>Nature</i> , 1995, 377, 68-71.	27.8	1,113
10	Sepsis: a roadmap for future research. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 581-614.	9.1	827
11	Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes. <i>Clinical Infectious Diseases</i> , 2008, 46, 201-211.	5.8	823
12	The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. <i>Critical Care Medicine</i> , 2005, 33, 1538-1548.	0.9	714
13	Protection from septic shock by neutralization of macrophage migration inhibitory factor. <i>Nature Medicine</i> , 2000, 6, 164-170.	30.7	709
14	High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. <i>American Journal of Medicine</i> , 1991, 91, 23-29.	1.5	578
15	Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. <i>Nature</i> , 2000, 408, 211-216.	27.8	539
16	MIF regulates innate immune responses through modulation of Toll-like receptor 4. <i>Nature</i> , 2001, 414, 920-924.	27.8	537
17	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017, 102, 433-444.	3.5	468
18	Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. <i>Critical Care Medicine</i> , 1999, 27, 1066-1072.	0.9	433

#	ARTICLE	IF	CITATIONS
19	Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF). <i>Biochemistry</i> , 1994, 33, 14144-14155.	2.5	405
20	Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991â€“2000. <i>Clinical Infectious Diseases</i> , 2004, 38, 311-320.	5.8	401
21	Dominant TNF-Î±+ Mycobacterium tuberculosisâ€“specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011, 17, 372-376.	30.7	380
22	Ceftazidime Combined with a Short or Long Course of Amikacin for Empirical Therapy of Gram-Negative Bacteremia in Cancer Patients with Granulocytopenia. <i>New England Journal of Medicine</i> , 1987, 317, 1692-1698.	27.0	368
23	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	5.8	368
24	Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. <i>New England Journal of Medicine</i> , 1999, 341, 312-318.	27.0	360
25	Changes in the epidemiological landscape of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i4-i13.	3.0	349
26	Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. <i>Microbes and Infection</i> , 2002, 4, 449-460.	1.9	314
27	Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. <i>Blood</i> , 2011, 117, 1205-1217.	1.4	311
28	Bacteremia due to viridans streptococci in neutropenic patients: A review. <i>American Journal of Medicine</i> , 1994, 97, 256-264.	1.5	285
29	Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome. <i>PLoS Pathogens</i> , 2009, 5, e1000480.	4.7	285
30	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
31	Invasive candidiasis as a cause of sepsis in the critically ill patient. <i>Virulence</i> , 2014, 5, 161-169.	4.4	255
32	1,3-Î±-D-Glucan Antigenemia for Early Diagnosis of Invasive Fungal Infections in Neutropenic Patients with Acute Leukemia. <i>Clinical Infectious Diseases</i> , 2008, 46, 878-885.	5.8	254
33	Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2348-2352.	7.1	252
34	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. <i>Critical Care</i> , 2010, 14, R222.	5.8	250
35	The Macrophage Migration Inhibitory Factor-Glucocorticoid Dyad: Regulation of Inflammation and Immunity. <i>Molecular Endocrinology</i> , 2007, 21, 1267-1280.	3.7	232
36	CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTS. <i>Lancet</i> , The, 1989, 334, 1437-1440.	13.7	213

#	ARTICLE	IF	CITATIONS
37	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2005, 52, 3020-3029.	6.7	203
38	Impact of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry on the Clinical Management of Patients With Gram-negative Bacteremia: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 1101-1107.	5.8	197
39	<i>Escherichia coli</i> Resistant to Fluoroquinolones in Patients with Cancer and Neutropenia. <i>New England Journal of Medicine</i> , 1994, 330, 1240-1241.	27.0	195
40	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013, 210, 1109-1116.	8.5	193
41	Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock. <i>Thrombosis and Haemostasis</i> , 1989, 61, 459-462.	3.4	186
42	Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System. <i>Critical Reviews in Immunology</i> , 1997, 17, 77-88.	0.5	186
43	$\beta$ -Glucan Antigenemia Anticipates Diagnosis of Blood Culture "Negative Intraabdominal Candidiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1100-1109.	5.6	183
44	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2012, 55, 381-390.	5.8	178
45	Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. <i>Cellular Signalling</i> , 2006, 18, 688-703.	3.6	177
46	Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. <i>European Journal of Immunology</i> , 2005, 35, 3405-3413.	2.9	174
47	Bench-to-bedside review: <i>Candida</i> infections in the intensive care unit. <i>Critical Care</i> , 2008, 12, 204.	5.8	174
48	Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. <i>Critical Care Medicine</i> , 2004, 32, S495-S512.	0.9	172
49	Science, medicine, and the future: Pathogenesis of sepsis: new concepts and implications for future treatment. <i>BMJ: British Medical Journal</i> , 2003, 326, 262-266.	2.3	171
50	Localization of Macrophage Migration Inhibitory Factor (MIF) to Secretory Granules within the Corticotrophic and Thyrotrophic Cells of the Pituitary Gland. <i>Molecular Medicine</i> , 1995, 1, 781-788.	4.4	170
51	New strategies for clinical trials in patients with sepsis and septic shock. <i>Critical Care Medicine</i> , 2001, 29, 880-886.	0.9	157
52	Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. <i>Journal of Molecular Medicine</i> , 1998, 76, 151-161.	3.9	153
53	Biochemical and Mutational Investigations of the Enzymatic Activity of Macrophage Migration Inhibitory Factor. <i>Biochemistry</i> , 1997, 36, 15356-15362.	2.5	149
54	Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. <i>Critical Care Medicine</i> , 2009, 37, 2929-2938.	0.9	140

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. <i>Aids</i> , 2007, 21, 441-446.	2.2	139
56	Antibiotics for Sepsisâ€”Finding the Equilibrium. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1433.	7.4	136
57	Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. <i>Critical Care Medicine</i> , 2005, 33, 1708-1716.	0.9	131
58	The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. <i>Journal of Clinical Investigation</i> , 2000, 106, 1291-1300.	8.2	127
59	Antibiotics in sepsis. <i>Intensive Care Medicine</i> , 2001, 27, S33-S48.	8.2	126
60	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	8.2	123
61	Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of <i>Plasmodium chabaudi</i> -Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial Anemia. <i>Infection and Immunity</i> , 2000, 68, 2259-2267.	2.2	120
62	Macrophage Migration Inhibitory Factor: Gene Polymorphisms and Susceptibility to Inflammatory Diseases. <i>Clinical Infectious Diseases</i> , 2005, 41, S513-S519.	5.8	119
63	Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 248-256.	5.8	114
64	Sepsis studies need new direction. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 503-505.	9.1	111
65	Resistance of <i>Candida</i> spp. to antifungal drugs in the ICU: where are we now?. <i>Intensive Care Medicine</i> , 2014, 40, 1241-1255.	8.2	111
66	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	5.8	109
67	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- <i>N</i>-Oxide, Anidulafungin, and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5303-5315.	3.2	108
68	Sepsis: Time to reconsider the concept. <i>Critical Care Medicine</i> , 2008, 36, 964-966.	0.9	107
69	Estradiol and Progesterone Strongly Inhibit the Innate Immune Response of Mononuclear Cells in Newborns. <i>Infection and Immunity</i> , 2011, 79, 2690-2698.	2.2	107
70	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
71	Critical Role of Lipopolysaccharide-Binding Protein and CD14 in Immune Responses against Gram-Negative Bacteria. <i>Journal of Immunology</i> , 2001, 167, 2759-2765.	0.8	103
72	Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1321-1328.	5.8	98

#	ARTICLE	IF	CITATIONS
73	Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor. <i>Journal of Biological Chemistry</i> , 2007, 282, 29910-29918.	3.4	97
74	Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 95-101.	1.8	96
75	Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2017, 25, 108.	2.6	96
76	Understanding and Enhancing Sepsis Survivorship. Priorities for Research and Practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 972-981.	5.6	96
77	Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 137-143.	3.2	94
78	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	5.8	94
79	Risk factors for candidemia: a prospective matched case-control study. <i>Critical Care</i> , 2020, 24, 109.	5.8	92
80	Molecular basis of host-pathogen interaction in septic shock. <i>Current Opinion in Microbiology</i> , 1998, 1, 49-55.	5.1	89
81	Early diagnosis of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i19-i28.	3.0	87
82	Histone Deacetylase Inhibitors Impair Antibacterial Defenses of Macrophages. <i>Journal of Infectious Diseases</i> , 2011, 204, 1367-1374.	4.0	83
83	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016, 20, 125.	5.8	83
84	Identification and Characterization of Novel Classes of Macrophage Migration Inhibitory Factor (MIF) Inhibitors with Distinct Mechanisms of Action. <i>Journal of Biological Chemistry</i> , 2010, 285, 26581-26598.	3.4	80
85	Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 ( <i>Tlr4</i> ) gene expression. <i>Biochemical Journal</i> , 2005, 387, 355-365.	3.7	78
86	Macrophage Migration Inhibitory Factor and Host Innate Immune Responses to Microbes. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 573-576.	1.5	77
87	Innate immunogenetics: a tool for exploring new frontiers of host defence. <i>Lancet Infectious Diseases</i> , 2007, 7, 531-542.	9.1	76
88	Bloodstream and endovascular infections due to <i>Abiotrophia defectiva</i> and <i>Granulicatella</i> species. <i>BMC Infectious Diseases</i> , 2006, 6, 9.	2.9	73
89	Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy—EORTC Infectious Diseases Group Trial XV. <i>Journal of Clinical Oncology</i> , 2013, 31, 1149-1156.	1.6	72
90	Macrophage Migration Inhibitory Factor and Host Innate Immune Defenses against Bacterial Sepsis. <i>Journal of Infectious Diseases</i> , 2003, 187, S385-S390.	4.0	71

#	ARTICLE	IF	CITATIONS
91	Macrophage Migration Inhibitory Factor Deficiency Is Associated With Impaired Killing of Gram-Negative Bacteria by Macrophages and Increased Susceptibility to <i>Klebsiella pneumoniae</i> Sepsis. <i>Journal of Infectious Diseases</i> , 2013, 207, 331-339.	4.0	71
92	Macrophage migration inhibitory factor and innate immune responses to bacterial infections. <i>Critical Care Medicine</i> , 2001, 29, S13-S15.	0.9	68
93	High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E997-1005.	7.1	67
94	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 4888.	12.8	67
95	A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses. <i>PLoS ONE</i> , 2011, 6, e24244.	2.5	67
96	Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. <i>Intensive Care Medicine</i> , 2009, 35, 903-908.	8.2	62
97	Lack of <i>Mycobacterium tuberculosis</i> -specific interleukin-17A-producing CD4 <sup>+</sup> T cells in active disease. <i>European Journal of Immunology</i> , 2013, 43, 939-948.	2.9	60
98	Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. <i>European Journal of Immunology</i> , 2007, 37, 3509-3521.	2.9	59
99	Initial antimicrobial management of sepsis. <i>Critical Care</i> , 2021, 25, 307.	5.8	58
100	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2005, 40, 239-245.	5.8	56
101	Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3597-3602.	7.1	55
102	Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). <i>Journal of Endotoxin Research</i> , 2003, 9, 119-123.	2.5	53
103	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
104	Transcriptional Activation of the Macrophage Migration-Inhibitory Factor Gene by the Corticotropin-Releasing Factor is Mediated by the Cyclic Adenosine 3',5'-Monophosphate Responsive Element-Binding Protein CREB in Pituitary Cells. <i>Molecular Endocrinology</i> , 1998, 12, 698-705.	3.7	51
105	Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 32-42.	2.2	51
106	A New Class of Isothiocyanate-Based Irreversible Inhibitors of Macrophage Migration Inhibitory Factor. <i>Biochemistry</i> , 2009, 48, 9858-9870.	2.5	51
107	A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. <i>FASEB Journal</i> , 2012, 26, 907-916.	0.5	50
108	Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the $\beta$ -Sheet Structure of MIF. <i>Journal of Biological Chemistry</i> , 2012, 287, 7446-7455.	3.4	50

#	ARTICLE	IF	CITATIONS
109	Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1749-1758.	4.1	48
110	Species-Specific Recognition of <i>Aspergillus fumigatus</i> by Toll-like Receptor 1 and Toll-like Receptor 6. <i>Journal of Infectious Diseases</i> , 2012, 205, 944-954.	4.0	48
111	The emerging role of MIF in septic shock and infection. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1994, 8, 123-127.	0.7	47
112	Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. <i>Trends in Microbiology</i> , 1994, 2, 198-201.	7.7	45
113	Macrophage Migration Inhibitory Factor Reduces the Growth of Virulent <i>Mycobacterium tuberculosis</i> in Human Macrophages. <i>Infection and Immunity</i> , 2005, 73, 3783-3786.	2.2	45
114	Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. <i>Critical Care</i> , 2012, 16, R114.	5.8	44
115	Treatment of Sepsis. <i>Drugs</i> , 1999, 57, 127-132.	10.9	43
116	Clinical Trials of Antifungal Prophylaxis among Patients Undergoing Surgery. <i>Clinical Infectious Diseases</i> , 2004, 39, S185-S192.	5.8	42
117	Role of TLR1, TLR2 and TLR6 in the modulation of intestinal inflammation and <i>Candida albicans</i> elimination. <i>Gut Pathogens</i> , 2017, 9, 9.	3.4	41
118	Infections in neutropenic cancer patients. <i>Lancet, The</i> , 2002, 359, 723-725.	13.7	39
119	Monitoring Procalcitonin in Febrile Neutropenia: What Is Its Utility for Initial Diagnosis of Infection and Reassessment in Persistent Fever?. <i>PLoS ONE</i> , 2011, 6, e18886.	2.5	39
120	Changing face of health-care associated fungal infections. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 314-319.	3.1	37
121	Rational approach in the management of <i>Pseudomonas aeruginosa</i> infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 578-586.	3.1	37
122	Antifungals in the ICU. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 610-619.	3.1	36
123	Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 137-149.	3.1	36
124	A role for the endocrine and pro-inflammatory mediator MIF in the control of insulin secretion during stress. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 47-54.	4.0	33
125	Role of Plasma, Lipopolysaccharide-Binding Protein, and CD14 in Response of Mouse Peritoneal Exudate Macrophages to Endotoxin. <i>Infection and Immunity</i> , 2001, 69, 378-385.	2.2	32
126	Antibiotic Usage and Resistance. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2367.	7.4	32



#	ARTICLE	IF	CITATIONS
127	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. <i>Cytokine</i> , 2006, 36, 51-56.	3.2	31
128	Glucocorticoid-induced MIF expression by human CEM T cells. <i>Cytokine</i> , 2009, 48, 177-185.	3.2	31
129	Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. <i>Intensive Care Medicine</i> , 2005, 31, 1514-1521.	8.2	30
130	Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. <i>Journal of Endocrinology</i> , 2010, 206, 297-306.	2.6	30
131	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. <i>PLoS ONE</i> , 2012, 7, e35485.	2.5	30
132	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. <i>Journal of Virology</i> , 2015, 89, 970-988.	3.4	30
133	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. <i>PLoS ONE</i> , 2012, 7, e48524.	2.5	30
134	Cytokines and septic shock. <i>Diagnostic Microbiology and Infectious Disease</i> , 1990, 13, 377-381.	1.8	29
135	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. <i>Shock</i> , 2007, 27, 482-487.	2.1	29
136	Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. <i>Frontiers in Immunology</i> , 2017, 8, 26.	4.8	29
137	Prognostic value of quickSOFA as a predictor of 28-day mortality among febrile adult patients presenting to emergency departments in Dar es Salaam, Tanzania. <i>PLoS ONE</i> , 2018, 13, e0197982.	2.5	27
138	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. <i>Haematologica</i> , 2018, 103, e527-e530.	3.5	26
139	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa075.	0.9	26
140	Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C. <i>PLoS ONE</i> , 2013, 8, e74831.	2.5	25
141	<i>Coxiella burnetii</i> vascular graft infection. <i>BMC Infectious Diseases</i> , 2005, 5, 109.	2.9	24
142	Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock. <i>Journal of Infection</i> , 2021, 82, 125-134.	3.3	22
143	Invasive mould infections: a multi-disciplinary update. <i>Medical Mycology</i> , 2009, 47, 571-583.	0.7	21
144	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. <i>Cytokine</i> , 2012, 60, 338-340.	3.2	21

#	ARTICLE	IF	CITATIONS
145	The need for aminoglycosides in combination with $\beta$ -lactams for high-risk, febrile neutropaenic patients with leukaemia. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 13-22.	2.2	20
146	Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. <i>Journal of Mass Spectrometry</i> , 2007, 42, 440-449.	1.6	20
147	The Role of Macrophage Migration Inhibitory Factor in Mouse Islet Transplantation. <i>Transplantation</i> , 2008, 86, 1361-1369.	1.0	20
148	IRF5 Is a Key Regulator of Macrophage Response to Lipopolysaccharide in Newborns. <i>Frontiers in Immunology</i> , 2018, 9, 1597.	4.8	20
149	Macrophage migration inhibitory factor promotes the migration of dendritic cells through CD74 and the activation of the Src/PI3K/myosin II pathway. <i>FASEB Journal</i> , 2021, 35, e21418.	0.5	20
150	Emerging single-cell technologies in immunology. <i>Journal of Leukocyte Biology</i> , 2015, 98, 23-32.	3.3	19
151	Let's add invasive aspergillosis to the list of influenza complications. <i>Lancet Respiratory Medicine</i> , 2018, 6, 733-735.	10.7	19
152	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	7.2	19
153	Antifungal prophylaxis for intensive care unit patients: let's fine tune it. <i>Intensive Care Medicine</i> , 2002, 28, 1698-1700.	8.2	17
154	Expression and Function of Macrophage Migration Inhibitory Factor (MIF) in Melioidosis. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e605.	3.0	17
155	Polymorphisms in Tumor Necrosis Factor- $\beta$ Increase Susceptibility to Intra-Abdominal Candida Infection in High-Risk Surgical ICU Patients*. <i>Critical Care Medicine</i> , 2014, 42, e304-e308.	0.9	17
156	Monocyte deactivation in septic shock. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 279-284.	3.1	16
157	<i>Histoplasma capsulatum</i> var. <i>duboisii</i> infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 85-89.	1.8	16
158	Role of MyD88 and Toll-Like Receptors 2 and 4 in the Sensing of <i>Parachlamydia acanthamoebae</i> . <i>Infection and Immunity</i> , 2010, 78, 5195-5201.	2.2	16
159	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 386-388.	2.5	15
160	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab471.	0.9	15
161	Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis. <i>PLoS ONE</i> , 2016, 11, e0163542.	2.5	15
162	<i>Candida</i> Arteritis in Patients Who Have Not Received Organ Transplants: Case Report and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2008, 46, e106-e111.	5.8	14

#	ARTICLE	IF	CITATIONS
163	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. <i>Clinical Immunology</i> , 2007, 123, 60-65.	3.2	13
164	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. <i>Journal of Infection</i> , 2018, 76, 489-495.	3.3	13
165	An Early Warning Score to predict ICU admission in COVID-19 positive patients. <i>Journal of Infection</i> , 2020, 81, 816-846.	3.3	13
166	High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure. <i>Intensive Care Medicine Experimental</i> , 2022, 10, 5.	1.9	13
167	Cytokines in septic shock. <i>Current Clinical Topics in Infectious Diseases</i> , 2002, 22, 1-23.	0.3	12
168	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. <i>Mycoses</i> , 2021, 64, 1512-1520.	4.0	11
169	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. <i>Journal of Virology</i> , 2015, 89, 3819-3832.	3.4	10
170	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e049232.	1.9	10
171	Exhaustion is Associated With Low Macrophage Migration Inhibitory Factor Expression in Patients With Coronary Artery Disease. <i>Psychosomatic Medicine</i> , 2007, 69, 68-73.	2.0	9
172	TLR2-mediated neutrophil depletion exacerbates bacterial sepsis: Fig. 1.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6889-6890.	7.1	9
173	Interleukin-33 safeguards neutrophils in sepsis. <i>Nature Medicine</i> , 2010, 16, 638-639.	30.7	9
174	COVID-19 rapidly increases MDSCs and prolongs innate immune dysfunctions. <i>European Journal of Immunology</i> , 2022, 52, 1676-1679.	2.9	9
175	Invasive <i>Candida</i> infections in the ICU. <i>Mycoses</i> , 2012, 55, 65-72.	4.0	8
176	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). <i>British Journal of Haematology</i> , 2000, 109, 396-404.	2.5	7
177	A New Step toward Individualized Antifungal Prevention in Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2009, 49, 733-735.	5.8	6
178	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 665-667.	3.0	6
179	Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?. <i>Current Opinion in Critical Care</i> , 2010, 16, 442-444.	3.2	6
180	What's new in antimicrobial use and resistance in critically ill patients?. <i>Intensive Care Medicine</i> , 2014, 40, 422-426.	8.2	6

#	ARTICLE	IF	CITATIONS
181	Invasive Pulmonary Aspergillosis Goes Viral Again?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 275-277.	5.6	6
182	Cytokines and <i>Escherichia coli</i> Sepsis. EcoSal Plus, 2006, 2, .	5.4	4
183	Modulation of human memory T cell function by different antigen-presenting cells. European Journal of Immunology, 2012, 42, 799-802.	2.9	3
184	Plant Immune Responses: Aphids Strike Back. Current Biology, 2015, 25, R604-R606.	3.9	3
185	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. Clinical Microbiology and Infection, 2022, 28, 611.e1-611.e7.	6.0	3
186	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. Studies in Health Technology and Informatics, 2020, 270, 1163-1167.	0.3	3
187	The Generation of Inflammatory Responses. , 2002, , 687-727.		2
188	Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock. , 2002, , 539-558.		2
189	Infections in the Cancer Patient. , 2017, , 723-738.e3.		2
190	Macrophage Migration Inhibitory Factor (MIF): A Pro-Inflammatory Mediator of Sepsis. Perspectives on Critical Care Infectious Diseases, 2001, , 45-67.	0.1	2
191	Clinical expert round table discussion (session 1) at the Margaux Conference on Critical Illness: Innate immunity: Host recognition of and sensitivity to bacterial components. Critical Care Medicine, 2001, 29, S19-S20.	0.9	1
192	Host Innate Immune Responses to Microbial Pathogens. Current Vascular Pharmacology, 2013, 11, 123-132.	1.7	1
193	Response to van Saene et al.'s comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients". Intensive Care Medicine, 2003, 29, 1196-1196.	8.2	0
194	MIF in Innate Immunity and Infectious Diseases. , 2007, , 107-132.		0
195	Fully human anti-macrophage migration inhibitory factor antibodies as potential therapeutics for sepsis and septic shock. Critical Care, 2008, 12, P15.	5.8	0
196	Reply to Pasqualotto and Sukiennik. Clinical Infectious Diseases, 2008, 47, 293-294.	5.8	0
197	Epigenetic Control of MIF Expression. , 2012, , 121-137.		0
198	A revival for immunoglobulin therapy in septic shock?. Intensive Care Medicine, 2014, 40, 1957-1959.	8.2	0

#	ARTICLE	IF	CITATIONS
199	Antimicrobial Therapy. , 2018, , 185-199.		0
200	Gas6 and Its Receptors Are Implicated in Sepsis as Modulators of Innate Immunity.. Blood, 2007, 110, 2409-2409.	1.4	0
201	Infections in the neutropenic cancer patient. , 2010, , 804-820.		0